Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CBRS18089 / S1418 / Alissa Huston

Basic Study Information

Purpose:
This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher:  Alissa Huston

Study Contact Information

Study Coordinator: Lauren Mitchell
Email: lauren_mitchell@urmc.rochester.edu

Additional Study Details

Return to Search